Blend Vial strength 12 mg Blend
AOD-9604 + CJC-1295 + Ipamorelin12 mg Blend
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
AOD-9604 + CJC-1295 + Ipamorelin, explained simply
A blend of three compounds investigated through different metabolic and growth hormone-related pathways.
Research area
Body composition and the GH/IGF-1 axis
How it works
AOD-9604 is studied in fat metabolism, CJC-1295 stimulates the GHRH pathway, and ipamorelin acts at a ghrelin receptor involved in GH release.
Why it matters
The combination is examined in the context of body composition and growth hormone axis responses.
What has been observed
Much of the cited evidence concerns the individual ingredients and their biological pathways. It does not establish an added benefit from the prepared blend.
Effects and points to consider
Ingredient amounts and total blend concentration matter when interpreting the figures; local reactions are also possible.
01 / Vial strength 12 mg Blend
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Total vial mass | 12 mg |
|---|---|
| Component masses | AOD-9604: 6 mg; CJC-1295: 3 mg; Ipamorelin: 3 mg |
| Final volume | 3 mL |
| Concentration | 4 mg/mL |
| Frequency | once daily |
| Cycle | 8-12; optional 16 in protocol overview |
Standard / Gradual Approach (3 mL reconstitution)
| Week | Daily Dose | Units (mL) |
|---|---|---|
| Week 1 | 200 mcg AOD / 100 mcg CJC / 100 mcg Ip | 10 units (0.10 mL) |
| Week 2 | 300 mcg AOD / 150 mcg CJC / 150 mcg Ip | 15 units (0.15 mL) |
| Weeks 3–12 | 400 mcg AOD / 200 mcg CJC / 200 mcg Ip | 20 units (0.20 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.